Valeant's Debt Agreement Comes With Freedom to Miss Forecast

Valeant's Debt Agreement Comes With Freedom to Miss Forecast


Valeant Pharmaceuticals International Inc.'s newly renegotiated agreement with lenders will let the drugmaker cut or miss financial projections that some analysts already thought it would struggle to meet. Under its previous agreement with lenders, Valeant would have had to produce trailing 12-month adjusted Ebitda of at least $4.675 billion to avoid breaching its credit pact.



from Biotech News